Edwards Lifesciences (EW) posted astonishing numbers on its new Sapien 3 heart valve and it will soon be the standard for heart doctors worldwide, said TheStreet's Jim Cramer. He said the stock has been on a tremendous run, but it remains a good buy because of the outlook for Sapien 3.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.